TY - JOUR
T1 - Curcumin-induced antitumor effects on triple-negative breast cancer patient-derived xenograft tumor mice through inhibiting salt-induced kinase-3 protein
AU - Cheng, Tzu Chun
AU - Sayseng, John Oliver
AU - Tu, Shih Hsin
AU - Juan, Ting Ching
AU - Fang, Chia Lang
AU - Liao, You Cheng
AU - Chu, Cheng Ying
AU - Chang, Hui Wen
AU - Yen, Yun
AU - Chen, Li Ching
AU - Ho, Yuan Soon
N1 - Publisher Copyright:
© 2021 Taiwan Food and Drug Administration.
PY - 2021
Y1 - 2021
N2 - This study demonstrated for the first time that curcumin effectively inhibits the growth of triple-negative breast cancer (TNBC) tumors by inhibiting the expression of salt-induced kinase-3 (SIK3) protein in patient-derived xenografted tumor mice (TNBC-PDX). For TNBC patients, chemotherapy is the only option for postoperative adjuvant treatment. In this study, we detected the SIK3 mRNA expression in paired-breast cancer tissues by qPCR analysis. The results revealed that SIK3 mRNA expression was significantly higher in tumor tissues when compared to the normal adjacent tissues (73.25 times, n = 183). Thus, it is proposed for the first time that the antitumor effect induced by curcumin by targeting SIK3 can be used as a novel strategy for the therapy of TNBC tumors. In vitro mechanism studies have shown that curcumin (>25 mM) inhibits the SIK3-mediated cyclin D upregulation, thereby inhibiting the G1/S cell cycle and arresting TNBC (MDA-MB-231) cancer cell growth. The SIK3 overexpression was associated with increased mesen-chymal markers (i.e., Vimentin, a-SMA, MMP3, and Twist) during epithelialemesenchymal transition (EMT). Our results demonstrated that curcumin inhibits the SIK3-mediated EMT, effectively attenuating the tumor migration. For clinical indications, dietary nutrients (such as curcumin) as an adjuvant to chemotherapy should be helpful to TNBC patients because the current trend is to shrink the tumor with preoperative chemotherapy and then perform surgery. In addition, from the perspective of chemoprevention, curcumin has excellent clinical application value.
AB - This study demonstrated for the first time that curcumin effectively inhibits the growth of triple-negative breast cancer (TNBC) tumors by inhibiting the expression of salt-induced kinase-3 (SIK3) protein in patient-derived xenografted tumor mice (TNBC-PDX). For TNBC patients, chemotherapy is the only option for postoperative adjuvant treatment. In this study, we detected the SIK3 mRNA expression in paired-breast cancer tissues by qPCR analysis. The results revealed that SIK3 mRNA expression was significantly higher in tumor tissues when compared to the normal adjacent tissues (73.25 times, n = 183). Thus, it is proposed for the first time that the antitumor effect induced by curcumin by targeting SIK3 can be used as a novel strategy for the therapy of TNBC tumors. In vitro mechanism studies have shown that curcumin (>25 mM) inhibits the SIK3-mediated cyclin D upregulation, thereby inhibiting the G1/S cell cycle and arresting TNBC (MDA-MB-231) cancer cell growth. The SIK3 overexpression was associated with increased mesen-chymal markers (i.e., Vimentin, a-SMA, MMP3, and Twist) during epithelialemesenchymal transition (EMT). Our results demonstrated that curcumin inhibits the SIK3-mediated EMT, effectively attenuating the tumor migration. For clinical indications, dietary nutrients (such as curcumin) as an adjuvant to chemotherapy should be helpful to TNBC patients because the current trend is to shrink the tumor with preoperative chemotherapy and then perform surgery. In addition, from the perspective of chemoprevention, curcumin has excellent clinical application value.
KW - Curcumin
KW - Epithelial-mesenchymal transition
KW - Patient-derived xenografted mice
KW - Salt-induced kinase-3
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85124520470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124520470&partnerID=8YFLogxK
U2 - 10.38212/2224-6614.3387
DO - 10.38212/2224-6614.3387
M3 - Article
AN - SCOPUS:85124520470
SN - 1021-9498
VL - 29
SP - 622
EP - 637
JO - Journal of Food and Drug Analysis
JF - Journal of Food and Drug Analysis
IS - 4
M1 - 6
ER -